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COVID-19 emergency use authorizations and approvals for vaccines were achieved in
record time. However, there remains a need to develop additional safe, effective, easy-toproduce, and inexpensive prevention to reduce the risk of acquiring SARS-CoV-2
infection. This need is due to difﬁculties in vaccine manufacturing and distribution,
vaccine hesitancy, and, critically, the increased prevalence of SARS-CoV-2 variants
with greater contagiousness or reduced sensitivity to immunity. Antibodies from eggs of
hens (immunoglobulin Y; IgY) that were administered the receptor-binding domain (RBD)
of the SARS-CoV-2 spike protein were developed for use as nasal drops to capture the
virus on the nasal mucosa. Although initially raised against the 2019 novel coronavirus
index strain (2019-nCoV), these anti-SARS-CoV-2 RBD IgY surprisingly had
indistinguishable enzyme-linked immunosorbent assay binding against variants of
concern that have emerged, including Alpha (B.1.1.7), Beta (B.1.351), Delta
(B.1.617.2), and Omicron (B.1.1.529). This is different from sera of immunized or
convalescent patients. Culture neutralization titers against available Alpha, Beta, and
Delta were also indistinguishable from the index SARS-CoV-2 strain. Efforts to develop
these IgY for clinical use demonstrated that the intranasal anti-SARS-CoV-2 RBD IgY
preparation showed no binding (cross-reactivity) to a variety of human tissues and had an
excellent safety proﬁle in rats following 28-day intranasal delivery of the formulated IgY. A
double-blind, randomized, placebo-controlled phase 1 study evaluating single-ascending
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and multiple doses of anti-SARS-CoV-2 RBD IgY administered intranasally for 14 days in
48 healthy adults also demonstrated an excellent safety and tolerability proﬁle, and no
evidence of systemic absorption. As these antiviral IgY have broad selectivity against
many variants of concern, are fast to produce, and are a low-cost product, their use as
prophylaxis to reduce SARS-CoV-2 viral transmission warrants further evaluation.
Clinical Trial Registration: https://www.clinicaltrials.gov/ct2/show/NCT04567810,
identiﬁer NCT04567810.
Keywords: immunoglobulin Y, IgY, chicken immunoglobulin, infectious diseases, SARS-CoV-2, COVID-19, clinical
trial body

2 (hACE2) receptor that is used by the virus to gain cellular entry
(15). Viral binding to the hACE2 receptor is mediated by the spike
(S) protein on the surface of the viral envelope (16) for all SARSCoV-2 variants identiﬁed so far; even the highly mutated Omicron
variant, with 15 mutations in the receptor-binding domain (RBD)
of the S protein, is still dependent on hACE2 for its infectivity (11).
Therefore, the nasal mucosa is an excellent site as a critical barrier to
reduce SARS-CoV-2 entry; antibodies against the SARS-CoV-2
RBD can compete with viral binding to the hACE2 receptor. In
addition, antibodies on epithelial surfaces can greatly inhibit lateral
viral motility, agglutinate viral particles, and anchor the virus to the
extracellular matrix (17, 18), thus making intranasally administered
antibodies a potentially important antiviral strategy. Indeed,
intranasal antibody prophylaxis has been shown to be effective
against multiple viral pathogens in humans and veterinary
applications, including respiratory tract viruses (18). Thus,
covering the nasal mucosa with anti-SARS-CoV-2 antibodies
could prevent SARS-CoV-2 infection in naïve individuals and
may also reduce viral transmission from an infected individual by
reducing levels of active virus.
Because the RBD remains essential for SARS-CoV-2 infection,
even for variants of concern, we chose recombinant RBD of the S
protein (amino acids 328-533) as the immunogen. We next
considered the optimal species to raise anti-SARS-CoV-2
polyclonal antibodies and chose to immunize egg-laying hens to
enable fast, low-cost, and high-volume production. Antibodies
generated in commercial hens (immunoglobulin Y; IgY) are
concentrated in their eggs to 50-100 mg/egg (thus yielding
approximately 35 g of IgY per year) within 2-3 weeks following
vaccination (19–21). This yield can be up to ﬁve times higher (175 g
of IgY in one year) when using speciﬁc-pathogen-free (SPF) hens.
Here, we describe the production of anti-SARS-CoV-2 RBD
IgY of the S protein in SPF hens and the characterization of these
IgY, including in culture neutralization efﬁcacy against current
pathogenic viral variants and a phase 1 study that evaluated the
safety, tolerability, and pharmacokinetics of anti-SARS-CoV-2
RBD IgY given by intranasal drops in healthy humans.

1 INTRODUCTION
As of May 1, 2022, over 510 million persons with coronavirus
disease 2019 (COVID-19) have been identiﬁed in 222 countries
and territories, resulting in an estimated 6.2 million deaths (1). It
is estimated that only 65% of the world population has been fully
vaccinated (2), a ﬁgure lower than believed needed to reach herd
(or community) immunity to stop the pandemic (3, 4). The
failure of virus- and vaccine-induced immunity to prevent
transmission has complicated this goal (5). Furthermore, only
15% of people in low-income countries have received at least one
vaccine dose to date (2).
The fast emergency regulatory authorizations and approvals of
COVID-19 vaccines in various countries were a critical turning
point in slowing the spread of the pandemic. However, there
remains a global need to develop additional safe, effective, easyto-produce, and inexpensive prophylaxis to prevent or reduce the
risk of acquiring severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection (6, 7). This need is due in part to the global
shortage of essential components necessary for manufacturing the
intramuscular mRNA vaccines and the requirement for cold chain
storage for distribution. In addition, novel means of prevention are
of heightened importance as variants of SARS-CoV-2 such as Delta
(B.1.617.20) and Omicron (B.1.1.529) increase contagiousness and
evade immunity produced by existing vaccines and previous
infection (8–13) and where COVID-19 vaccination is unavailable,
especially in resource-poor settings. These variants have occurred
even in populations with high vaccine uptake and are now the most
prevalent COVID-19 strains globally (14).
The main entry route for SARS-CoV-2 is the nasal mucosa,
which has high levels of the human angiotensin-converting enzyme
Abbreviations: COVID-19, coronavirus disease 2019; ELISA, enzyme-linked
immunosorbent assay; GLP, Good Laboratory Practice; GMP, Good
Manufacturing Practice; hACE2, human angiotensin-converting enzyme 2;
HPLC, high-performance liquid chromatography; HRP, horseradish peroxidase;
IC50, half-maximal inhibitory concentration; IgE, immunoglobulin E; IgG,
immunoglobulin G; IgM, immunoglobulin M; IgY, immunoglobulin Y; NT50,
50% neutralization titer; PFU, plaque-forming units; PK, pharmacokinetic; RBD,
receptor-binding domain; S, spike; SARS-CoV-2, severe acute respiratory
syndrome coronavirus 2; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel
electrophoresis; SPF, speciﬁc pathogen-free; SMC, Safety Monitoring Committee;
TCID50, tissue culture infective dose; USAMARIID, United States Army Medical
Research Institute of Infectious Diseases; VSV, vesicular stomatitis virus; VSV-S,
VSV expressing spike protein on its surface.
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2 MATERIALS AND METHODS
2.1 Study Design
The experiments were conducted in four parts: 1) production of
immunogen (recombinant RBD), immunization of 12 SPF hens,

2

June 2022 | Volume 13 | Article 899617

Frumkin et al.

Anti-SARS-CoV-2 IgY Intranasal Prophylaxis

IgY collection from egg yolks, and in vitro characterization of the
IgY anti-SARS CoV-2 RBD, 2) Good Laboratory Practice (GLP)blinded safety studies in rat, treated intranasally twice daily for
28 days with a total of 16 mg/kg IgY or vehicle, 3) a preliminary
efﬁcacy study of hamsters treated with IgY or phosphatebuffered saline for 4 hours before viral challenge, and 4) a
placebo-controlled, double-blind phase 1 safety, tolerability,
and pharmacokinetic (PK) study conducted in healthy humans
using intranasal IgY or vehicle in single-ascending doses
followed by multiple doses (3-times daily every 4 hours) for 14
days. Both the single-ascending and multiple-dose parts were
followed by a 7-day nontreatment period to further
evaluate safety.

SARS-CoV-2 Hu-1 spike, a truncated spike with a C-terminal 19
amino acid deletion; the Beta variant (K417N/E484K/N501Y/
D614G full-length spike); or a D614G spike variant with a fulllength sequence of the index spike protein. The neutralization
assay was performed with HEK 293T-hACE2, a human
embryonic kidney cell line overexpressing hACE2. For details,
see Supplementary Methods.

2.4.3 In Culture Neutralization Studies
Using Live Virus
At the United States Army Medical Research Institute of Infectious
Diseases (USAMARIID; Frederick, MD), all work with authentic
(live) SARS-CoV-2 (SARS-CoV-2/B.1.617.2) studies were
conducted in Biosafety Level 3 laboratories following federal and
institutional biosafety standards and regulations. Vero-76 cells were
inoculated for 1 hour with SARS-CoV-2/Was1 (MT020880.1) after
a 1 hour preincubation of the virus with control or anti SARS-CoV2 IgY antibodies. At 23 hours after infection, cells were washed, ﬁxed
in 10% formalin, and permeabilized with 0.2% Triton-X for 10
minutes. Detection of infection was accomplished using an antiSARS-CoV-2 nucleocapsid protein detection antibody
(Sino Biological).
At RetroVirox (San Diego, CA), puriﬁed IgY (lot Y0180) was
also tested against three live SARS-CoV-2 clinical isolates: MEXBC15/2021 (lineage B.1.617.2, Delta), USA/SD-RVX01/2022
(lineage B.1.529, Omicron) and MEX-BC2/2020 (lineage B.1,
carrying the D614G mutation) by infecting Vero E6 cells in the
presence or absence of test items. Virus-induced cytopathic effect
was monitored under the microscope after 3 days of infection.
Some cells were treated with plasma from an uninfected
individual who received two doses of Moderna’s mRNA
COVID-19 vaccine as a positive control. For more details, see
Supplementary Methods.

2.2 Recombinant SARS-CoV-2 RBD
and Characterization
SARS-CoV-2 RBD (residues 328-533) of the 2019 novel
coronavirus index virus (2019-nCoV) was expressed in cell-free
protein synthesis reactions at Sutro Biopharma, Inc. (South San
Francisco, CA) using the XpressCFTM platform (22, 23). Binding
kinetics of cell-free expressed SARS-CoV-2 RBD construct or
mammalian expressed his-tagged RBD control (ACROBiosystems
SPD-C52H1) were then measured on a Biacore T200 instrument,
using Fc-tagged hACE2 receptor protein (ACROBiosystems AC2H5257); see Supplementary Methods.

2.3 Hen Immunization and IgY Puriﬁcation
and Characterization
Nine SPF were hens immunized with an inoculum containing 50 µg
of recombinant cell-free expressed RBD fragment derived from S1
spike protein and water-in-oil adjuvant, boosted after 14 days, and
then boosted again 4 weeks later, unless otherwise indicated.
Nonfertilized eggs were collected weekly. Yolks in batches up to
100 eggs/batch were separated and IgY was puriﬁed using water
extraction, an established method to purify IgY (24–27). Hen sera
and puriﬁed IgY were tested by enzyme-linked immunosorbent
assay (ELISA) and Western blot analysis using both the immunogen
(RBD) and full length glycosylated S1 protein (ACROBiosystems,
cat# S1N-C5255). See Supplementary Methods for more details.

2.5 GMP IgY Formulation, Analytical
Studies, and Stability
Using Good Manufacturing Practice (GMP), anti-S1 RBD IgY
was formulated for use as intranasal drops as 0 (placebo control),
5, 10, and 20 mg/mL anti-S1 RBD IgY preparations in sterile 2%
microcrystalline cellulose and carboxymethylcellulose sodium at
Bravado Pharmaceuticals (Lutz, FL). The suspension was packed
in a 1.5-mL dropper bottle and tests for GMP drug product
release complied with the relevant standards and methods,
including microbiological examination of nonsterile products
(USP <1111>, <61> and <62>). All formulated products were
100% stable as measured by physical and analytical properties,
including high-performance liquid chromatography (HPLC),
when stored for at least 6 months at 2-8°C and about 1 month
when stored at room temperature.

2.4 Evaluation of IgY
2.4.1 ELISA Evaluation of IgY Titer Against SARSCoV-2 Variants of Concern
ELISA titer of the ﬁnal IgY preparation used in the clinical
studies against the Alpha, Beta, Delta, and Omicron-derived
RBD [amino acids 319-537; ACROBiosystems SPD-C52H1
(index), SPD-C52Hn (Alpha), SPD-C52Hp (Beta), SPD-C525e
(Delta), and SPD-C522e (Omicron)] was carried out as described
in Supplementary Methods.

2.6 GLP Rat Toxicity and Safety Study

2.4.2 In Culture Viral Neutralization Studies
Using Pseudovirus

Thirty-ﬁve female and 35 male >8-week-old Sprague Dawley rats
were used in a GLP study conducted at Charles River
Laboratories (Spencerville, OH). Water and food were freely
available. The experimental protocol is summarized in
Supplementary Tables S1-S3.

The neutralization assays using pseudovirus were performed at
RetroVirox (San Diego, CA). The assay used three non-replicative
vesicular stomatitis virus (VSV) pseudoviruses carrying a ﬁreﬂy
luciferase reporter gene and expressing the S proteins of the index
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described (29) were housed at the Washington University (St.
Louis, MO) Biosafety Level 3 facility in HEPA-ﬁltered rodent
cages. Before challenge with SARS-CoV-2, all animals received
100 mL of a placebo control ﬂuid or ﬂuid-formulated anti-SARSCoV-2 RBD IgY (1 mg/50 mL of the 20 mg/mL solution per
nare). Four hours after the delivery, the animals were challenged
with 104 or 5 x 104 plaque-forming units (PFU) of SARS-CoV-2
(titer determined on Vero-hACE2; see below).
The protocol included 18 hamsters in 4 planned groups:
Group 1: Control with 5 x 104 PFU (4 animals); Group 2:
Control with 1 x 104 PFU (4 animals); Group 3: Anti-SARSCoV-2 RBD IgY with 5 x 104 PFU (5 animals); and Group 4:
Anti-SARS-CoV-2 RBD IgY with 1 x 104 PFU (5 animals). Note
that the viral titer in Vero-hACE2-hTMPRSS2 cells, which
express the essential protease to liberate the RBD from the S
protein on the surface of the virus (30), was subsequently found
to be almost 100-fold higher for Groups 1 and 3 (4 x 106 PFU)
and Groups 2 and 4 (0.8 x 106 PFU). Three days after challenge,
the animals were sacriﬁced and lungs were collected. See
Supplementary Methods.

2.6.1 Cytokine Level Measurement and Analysis
This non-GLP blinded assay was performed on serum by
the Immunoassay Team at the Human Immune Monitoring
Center at Stanford University (Stanford, CA). Assay kits
(RECYMAG65K27PMX Rat) were purchased from EMD Millipore
and used according to the manufacturer’s recommendations, with
modiﬁcations described in Supplementary Methods.

2.6.2 IgY in Sera of Treated Rats
The presence of anti-SARS-CoV-2 IgY in sera of rats was
evaluated using GLP standards in a qualiﬁed ELISA assay at
Charles River Laboratories (Reno, NV). See Supplementary
Methods for more details.

2.7 Human Tissue Cross-Reactivity Study
A GLP study examining human tissue reactivity of the antiSARS-CoV-2 RBD IgY was conducted at Charles River
Laboratories (Frederick, MD) using at least 3 tissues from at
least 3 donors (Supplementary Table S4), using 10 mg/mL or 20
mg/mL IgY control (negative control) and anti-SARS-CoV-2
RBD IgY or an anti-human hypercalcemia of malignancy peptide
(amino acid residues 1-34, Sigma-Aldrich; Catalog No. H9148;
positive control), each in 1% bovine serum albumin. The slides
were then visualized by light microscopy.

2.9 Phase 1 Safety, Tolerability, and
Pharmacokinetic Study in Humans
2.9.1 Study Design and Dose Selection
A single-center, randomized, double-blind, placebo-controlled
phase 1 study of anti-SARS-CoV-2 RBD IgY given intranasally to
48 healthy adults was conducted at Linear Clinical Research-Harry
Perkins Research Institute (Nedlans, WA, Australia) (see Figure 1).
Written informed consent was obtained from all participants. The
study is registered at ClinicalTrials.gov: NCT04567810. The study
period was conducted between September 25, 2020 and December
14, 2020. The protocol for this trial is available as supporting
information (Supplementary Methods).
Healthy male and female participants ≥18 and ≤ 45 years old
with a body weight ≥ 50 kg and a body mass index ≥ 18.0 and ≤
32.0 kg/m2 were eligible for this study. Females of childbearing
potential who were pregnant or lactating or planning to become

2.8 Virus Preparation for the Efﬁcacy
Study in a Hamster Model of
COVID-19 and Quantitation of
Viral Load in the Animals
Syrian hamsters develop mild-to-moderate disease with
progressive weight loss that starts several days after SARSCoV-2 infection by intranasal inoculation (28, 29). SARS-CoV2 (strain 2019-nCoV/USA-WA1/2020) was propagated on VeroTMPRSS2 cells, and the virus titer was determined by plaque
assays on Vero-hACE2 and Vero-hACE2-TMPRSS2 cells. Fiveto 6-week-old Syrian golden hamsters (Charles River
Laboratories) infected with SARS-CoV-2 as previously

FIGURE 1 | Design of phase 1 human single-ascending and multiple-dose study.
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group manner. Up to 24 healthy participants were randomized to
1 of 4 treatment regimens (6 participants per regimen). The
following regimens were administered: 6 mg total daily dose antiSARS-CoV-2 RBD IgY preparation for 14 days, 12 mg total daily
dose anti-SARS-CoV-2 RBD IgY preparation for 14 days, 24 mg
total daily dose anti-SARS-CoV-2 RBD IgY preparation for 14
days, and 0 mg total daily dose placebo preparation for 14 days.
In Part 2, 2 drops were applied to each nostril every 4 hours (3times daily). A 7-day nontreatment follow-up period assessed
safety after completion of the dosing.
In each part, 3 groups with 8 healthy participants per group (6
active and 2 placebo in each group) were dosed. Safety and
tolerability were evaluated using adverse event, physical
examination (including vital signs), electrocardiogram, and
clinical laboratory data. PK of anti-SARS-CoV-2 RBD IgY was
evaluated by measuring serum concentrations pretreatment and
at Day 14 when given as multiple doses administered intranasally
for 14 days.
The investigational drug was supplied as a liquid preparation
in a nose drop bottle containing 1.5 mL anti-SARS-CoV-2 RBD
IgY preparation nasal suspension at 5, 10, or 20 mg/mL, or
placebo, for intranasal application. Each bottle of nasal drops had
enough material for one day of use. The liquid preparation
contained anti-SARS-CoV-2 RBD IgY 0.5 mg/100 µL/drop, 1
mg/100 µL/drop, or 2 mg/100 µL/drop. The total maximum daily
dose of anti-SARS-CoV-2 RBD IgY used in the present study (24
mg) was based in part on solubility considerations and is less
than the daily dose of anti- Pseudomonas aeruginosa IgY
previously given prophylactically as an oral (mouth rinse)
treatment to prevent pulmonary infections in 17 patients with
cystic ﬁbrosis (31). For the maximum anti-SARS-CoV-2 RBD
IgY dose of 4 mg/nare, we calculated a favorable ratio of IgY to
viral particles, even when virus covers the nasal pathway.
All participants were provided with a Dose Administration
Guide and instructed to “Gently blow your nose before using this
drug. Then tilt your head back while sitting or lying down. After
the study drug is administered, keep your head tilted for a few
minutes. Try not to blow your nose for at least 5 minutes after
study drug administration.”

pregnant during the study and participants with a history of
alcohol and drug abuse, current smoking, clinically signiﬁcant
laboratory abnormalities, history of nasal surgical procedures,
frequent or recurrent nasal conditions, current use of any nasal
preparations, evidence of or history of clinically signiﬁcant
conditions, or positive test for hepatitis B, hepatitis C, human
immunodeﬁciency virus, or SARS-CoV-2 nucleic acid or
serology were excluded from participation. Full eligibility
criteria are summarized in Supplementary Methods.
The master randomization schedule and the associated code
break envelope ﬁles were produced by an unblinded statistician
using a computer-generated (SAS® v9.4 PLAN procedure)
pseudo-random permutation procedure. For Part 1, the ﬁrst
two randomization numbers for each cohort were randomly
assigned in a 1:1 ratio (anti-SARS-CoV-2 IgY: Placebo) to allow
for sentinel dosing, and the remainder of the numbers for each
cohort was generated in a 5:1 (anti-SARS-CoV-2 IgY: Placebo)
ratio using a permuted blocked randomization with a block size
of six. For Part 2, 24 numbers were generated in a 1:1:1:1 ratio (6
mg anti-SARS-CoV-2 IgY: 12 mg anti-SARS-CoV-2 IgY: 24 mg
anti-SARS-CoV-2 IgY: Placebo) using a permuted blocked
randomization with a block size of six. The block sizes were
kept conﬁdential during the study.
The site personnel randomized eligible participants on Day 1
by assigning the next available randomization number for the
speciﬁc study part to the participant and reporting the
randomization number on the case report form. Study drug
was prepared by an unblinded pharmacist based on the
treatment corresponding to the assigned randomization
number on the randomization schedule that was only available
to the pharmacist. In the event of an emergency, authorized
personnel were able to unblind a participant through the code
break envelope associated with the randomization number
assigned to the participant.
In Part 1, participants were randomly assigned to receive a single
dose of anti-SARS-CoV-2 RBD IgY antibodies or placebo in a
sequential escalating manner. Three groups were sequentially dosed
with 8 healthy participants per group (6 active and 2 placebo in each
group). Each group in Part 1 included the initial dosing of a sentinel
group (1 anti-SARS-CoV-2 RBD IgY and 1 placebo) at least 24
hours before dosing the remaining 6 participants in the cohort (5
anti-SARS-CoV-2 RBD IgY and 1 placebo). The remainder of the
cohort were dosed if, in the opinion of the investigator, there were
no signiﬁcant safety concerns identiﬁed in the sentinel participants
within the ﬁrst 24 hours after administration of the dose (antiSARS-CoV-2 RBD IgY or placebo). A Safety Monitoring
Committee (SMC) reviewed safety data before each dose
escalation. The following regimens were administered: 2 mg antiSARS-CoV-2 RBD IgY preparation or placebo, 4 mg anti-SARSCoV-2 RBD IgY preparation or placebo, and 8 mg anti-SARS-CoV2 RBD IgY preparation or placebo. In Part 1, 2 drops were applied to
each nostril as a single administration. A 7-day nontreatment
follow-up period assessed safety after completion of the dosing.
In Part 2, participants were randomly assigned to receive
multiple daily administrations of anti-SARS-CoV-2 RBD IgY or
placebo every 4 hours (3-times daily) for 14 days in a parallel-
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2.9.2 Assessments
Safety (and tolerability) were evaluated using adverse event,
physical examination (including vital signs), electrocardiogram,
and clinical laboratory data that included nonfasted collection of
hematology, serum metabolic panel, coagulation, urinalysis, and
urine human chorionic gonadotropin values. Pharmacokinetics
following intranasal administration of anti-SARS-CoV-2 RBD
IgY were evaluated in the multiple-dose part of the study by
measuring serum anti-SARS-CoV-2 RBD IgY concentration
(lower limit of quantiﬁcation, 30 ng/mL) at baseline and 2
hours after ﬁnal dosing on Day 14, as described above (Charles
River Laboratories, Reno, NV).
Serum cytokine levels for exploratory analyses were evaluated
from the sera of 19 multiple-dose participants before and 2 hours
after dosing on Days 1 and 2, as described above (Stanford
Human Immune Monitoring Center, Stanford CA). An
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preferred term, severity, seriousness, and relationship to study
drug. In the event of multiple occurrences of the same adverse
event with the same preferred term in one participant, the
adverse event was counted once as the worst occurrence.
Summary statistics for actual values and change from baseline
were analyzed for laboratory results by treatment group and
scheduled visit. Data summarized by treatment included adverse
events, vital signs, electrocardiogram parameters, and clinical
laboratory evaluations.

exploratory analysis was conducted of pretreatment serum total
immunoglobulin E (IgE) and anti-IgE antibody (mainly antiovalbumin) levels in the 24 participants in the multiple-dose part
of the trial.

2.9.3 Changes in the Conduct of the Study
All participants were enrolled, treated, and assessed under
Protocol CVR001 version 3.0, dated 29 September 2020
(Supplementary Methods). The following changes were made
to the conduct of the study from what was speciﬁed in
the protocol:

2.9.6 Cytokine Measurement and Analysis
This non-GLP blinded assay was performed on the sera of study
participants by the Immunoassay Team at the Human Immune
Monitoring Center at Stanford University (Stanford, CA), as
described for the rat cytokine assay above. The levels of 80
different cytokines were determined.

• Participants were reconsented to allow for exploratory
cytokine analyses on stored blood samples.
• Per the study protocol, serum anti-SARS-CoV-2 IgY samples
were obtained from participants in the multiple-dose part of
the study before dosing and at 0.5, 1, 1.5, and 2 hours after
dosing on Days 1 and 14, as well as before dosing and 2 hours
after dosing on Days 2, 3, and 4. Because anti-SARS-CoV-2
IgY was not measurable at the time of the theoretical
maximum serum concentration at 2 hours postdose on Day
14, the remaining postbaseline PK samples were not analyzed.

2.9.7 GLP Bioanalytical Analysis of IgY in Blood
Samples – Toxicokinetic Analysis
The presence of anti-SARS-CoV-2 IgY in sera of study
participants was evaluated using GLP standards in a qualiﬁed
ELISA assay at Charles River Laboratories (Reno, NV) described
in Supplemental Methods.

2.9.4 Interim Analyses

2.10 Good Laboratory Practice

Before dose escalation in the single-ascending dose cohorts, the
SMC was to review all available safety and tolerability data for a
minimum of 7 participants who completed the planned safety
assessments up to 48 hours after dosing. The SMC comprised
three physician members (the principal investigator, sponsor
medical representative, and independent medical monitor). The
data was to be reviewed blinded, unless the SMC considered it
necessary to unblind the data for safety concerns. Before
breaking the code per standard procedures, the potential
decisions and actions were to be determined. SMC decisions
on dose escalation were to be taken in consensus between the
members of the SMC. The SMC decisions and their rationale
were documented.

The study was performed at Charles River Laboratories following
the U.S. Department of Health and Human Services, Food and
Drug Administration (FDA), United States Code of Federal
Regulations, Title 21, Part 58: Good Laboratory Practice for
Nonclinical Laboratory Studies and as accepted by Regulatory
Authorities throughout the European Union (OECD Principles
of Good Laboratory Practice), Japan (MHLW), and other
countries that are signatories to the OECD Mutual Acceptance
of Data Agreement.

2.11 Animal Welfare Assurance
and Standards
The protocols and any amendment(s) or procedures involving
the care and use of animals (hen immunization and rat
tolerability studies) were reviewed and approved by Charles
River Laboratories Institutional Animal Care and Use
Committee before conduct. The hamster efﬁcacy study was
conducted following the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of
Health and the protocol was approved by the Institutional
Animal Care and Use Committee at the Washington
University School of Medicine (assurance number A3381–01).
Stanford Institutional Animal Care and Use Committee did not
initially review the animal studies because they were not
conducted at Stanford but were retroactively approved.

2.9.5 Analyses
No formal sample size calculations were done. Based on
experience from previous similar studies, the target number of
participants was appropriate for the assessment of safety,
tolerability, and PK. The planned sample size was 48
participants. A total of 48 participants were enrolled and
included in the safety analyses. The analysis of safety variables
included all participants who received study drug. All variables
were summarized by descriptive statistics for each treatment
group. The statistics for continuous variables included mean,
median, standard deviation, and number of observations.
Categorical variables were tabulated using frequencies and
percentages. The incidence of all reported treatment-emergent
adverse events and treatment-related adverse events was
tabulated by treatment group. Adverse events were also
classiﬁed by system organ class and preferred term using the
Medical Dictionary for Regulatory Activities. Adverse events
were to be listed and summarized by treatment group,
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2.12 Regulatory and Ethics Considerations
Ethical review of the clinical trial protocol and any amendments
was obtained by Bellberry Human Research Ethics Committee
(Australian equivalent to U.S. Institutional Review Board) and
the clinical trial was conducted solely at a single investigative site,
Linear Clinical Research-Harry Perkins Research Institute
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receptor. Binding kinetics and afﬁnity were similar to a
mammalian expressed and glycosylated S1 fragment
(Figure 2D) and were consistent with previously described
binding afﬁnities, suggesting the RBD expressed cell-free was
properly folded and bioactive.

(Nedlands, Australia). Stanford Institutional Review Board did
not review the research. The study was conducted following the
protocol and ethical principles stated in the 2013 version of the
Declaration of Helsinki and the applicable guidelines on Good
Clinical Practice, and all applicable federal, state, and local laws,
rules, and regulations.

3.2 Hen Immunization With SARS-CoV-2
RBD and IgY Characterization In Vitro
Cell-free expressed RBD (Figure 2B; 50 µg in simple oil
emulsion) was injected into 9 SPF hens (46-weeks old) and IgY
was extracted from egg yolks using a water-based method 2
weeks after the second immunization and thereafter. The IgY
preparation was subjected to protein and Western blot analyses
(Figure 3A). The IgY preparations were >95% pure; a
quantitative Western blot analysis demonstrated that this
preparation contained less than 2% ovalbumin by weight
(Figure 3A). Chromatography of the IgY preparations on sizeexclusion HPLC identiﬁed 5 peaks (Figure 3B); SDS-PAGE and
Western blot analysis of the peaks collected between 17 and 30
minutes conﬁrmed that these peaks all contain IgY. The antiSARS-CoV-2 RBD IgY antibodies recognized both the
immunogen, cell-free expressed RBD, and the mammalianexpressed full-length and glycosylated S1 protein (Figure 3C).
One egg yolk of the SPF hens provided about 500 mg of puriﬁed
IgY and each of >10 independent batches of IgY, puriﬁed from
100 eggs, each yielded an average of 47 ± 13 g (SD) of puriﬁed

3 RESULTS
3.1 Antigen Production
The overall scheme describing the production of anti-SARS
CoV-2 IgY antibody to be used as intranasal prophylaxis in
humans is shown in Figure 2A. We produced a recombinant
protein to immunize hens. A tagless RBD of SARS-CoV-2
(Figure 2B; index SARS-CoV-2 variant), amino acids 328-533,
was produced in a cell-free protein synthesis reaction using E.coli
extract (19, 20, 29). Analysis of the puriﬁed CoV-2 RBD protein
yielded a single protein band with an apparent molecular weight
of 23 kDa (Figure 2C). The puriﬁed SARS-CoV-2 RBD was
eluted as a single peak by analytical size-exclusion
chromatography with >95% monomer content (Figure 2C).
Bacterial endotoxin contamination was determined to be <0.1
EU/mg by Charles River Endosafe LAL cartridge system.
Integrity of the cell-free (non-glycosylated) SARS-CoV-2
RBD was then veriﬁed by kinetic binding to the hACE2

A

B

C

D

FIGURE 2 | RBD and IgY preparation. (A) Workﬂow of the study. IgY preparation for intranasal drops as antiviral prophylaxis. (B) Cell-free expressed RBD derived
from the Spike protein on the viral envelope of SARS-CoV-2. (C) Characterization of the recombinant protein RBD by ELISA and HPLC. (D) Determination of the
afﬁnity of the cell-free expressed RBD (amino acids 328-533) and mammalian-expressed full-length S1 to the hACE2 using Biacore.
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A

B

C

D

E

G

F

H

FIGURE 3 | IgY puriﬁcation and characterization. (A) Western blot analysis of the IgY preparation. (B) HPLC proﬁle of the IgY preparation. (C) Western blot
analysis of anti-SARS-CoV-2 IgY against RBD fragment and full S1 recombinant protein. (D) IgY yield for various batches derived from 100 eggs each. (E)
Western blot data of different lots of anti-SARS-CoV-2 RBD IgY (Y0120-Y0199). Pools of 100 eggs laid by 9 hens over 2 weeks were used for each pool of IgY
preparation between May 2020 and March 2021. IgY lot samples were diluted 1:500 followed by a 1:3000 dilution of rabbit anti-IgY HRP conjugate. First left
lane shows the Coomassie stain of the same gels. (F) Time-dependent ELISA titers of sera from 3 individual hens following continual immunization (left); arrows
indicate immunization timing. Time-dependent ELISA titer of 3 hens after immunization was stopped for up to 12 weeks (right). (G) Neutralization of pseudovirus
SARS-CoV-2 by various lots of anti-SARS-CoV-2 RBD IgY (conducted at RetroVirox). (H) Neutralization of live index SARS-CoV-2 virus by anti-SARS-CoV-2
RBD IgY (Y0180, conducted at USAMRIID).

of the virion (VSV-S). The neutralization assay was performed
with HEK 293T-hACE2, a human embryonic kidney cell line
overexpressing hACE2, the receptor of the SARS-CoV-2 virus.
First, 5 batches of RBD IgY preparations were tested. The
neutralization activity of the puriﬁed IgY, deﬁned as the
concentration inhibiting 50% of the viruses (IC50) was ~170
µg/mL (Figure 3G). Importantly, ~10-fold higher neutralization
activity towards the index SARS-CoV-2 virus was observed when
using a live index virus (Figure 3H). Approximately 30 µg/mL
IgY provided 50% neutralization of the index virus in
culture (Figure 3H).
Because at least 13 common variants of SARS-CoV-2 with
amino acid mutations in the RBD had emerged since December
2020 (32–34) (Figure 4A), we tested the activity of the antiSARS-CoV-2 IgY against several variants (including Beta, Delta,
and Omicron; Figures 4A, B) and D614G, an amino acid
substitution outside the RBD that is now found in most
variants. Beta, Delta, and Omicron were classiﬁed as variants
of concern, associated with increased transmissibility or
detrimental change in COVID-19 epidemiology, or an increase
in virulence or change in clinical disease presentation.

IgY (see Figure 3D for select examples). There was limited
variability in the afﬁnity of the various IgY batches for the S
glycosylated protein as judged by ELISA (Figure 3D; average
titer against full-length S1 was 1:18,000). Furthermore, there was
almost no difference in titer of individual hens towards the fulllength glycosylated S protein, suggesting minimal variability
between hens (Figures 3E, F). Over 11 months, IgY was
collected in batches of 100 eggs per preparation with a similar
yield of IgY per preparation and a similar response; interruption
of immunizations for 3 months did not result in a drop in titer
(Figure 3F, right panel).

3.3 Neutralization of SARS-CoV-2 Index
Strain and Variants of Interest and
Concern With Anti-SARS-CoV-2 RBD IgY
Pseudoviruses are synthetic chimeras that consist of a surrogate
viral core derived from a parent virus and an envelope
glycoprotein derived from a heterologous virus (30). Viral
neutralization assays in culture (RetroVirox) used nonreplicative VSV pseudoviruses carrying a ﬁreﬂy luciferase
reporter gene and expressing S of SARS-CoV-2 on the surface
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I

FIGURE 4 | Common SARS-CoV-2 variants and anti-SARS-CoV-2 IgY interaction with them (A) A scheme depicting locations of mutated amino acids in Alpha
through Mu variants of SARS-CoV-2, focusing on the RBD domain only. Each color bar indicates the amino acid in the index virus that was mutated in the variant.
(B) Spike protein of SARS-CoV-2 Alpha, Beta, Delta, and Omicron are shown from left to right. Molecular Operating Environment was used to create the ﬁgure (35).
The location of mutations in the structure of the S protein trimer of SARS-CoV-2 (PDB ID: 7A98) for 4 of the common variants are indicated in red and glycosylation
sites are indicated in pink throughout the S protein. Blue ribbon indicates RBD (amino acids 328-533), and the orange ribbon indicates receptor binding motif (amino
acids 437-508). (C) Binding of anti-SARS-CoV-2 RBD IgY to recombinant S1 full length (FL) of the index virus, the RBD of the Alpha and Beta variants, and the
immunizing RBD of the index virus by ELISA. (D) Neutralization of pseudovirus (VSV-S) SARS-CoV-2 carrying S protein of index virus, Alpha, or Beta variants by antiRBD IgY. (E) Neutralization of live index or Delta viruses by anti-SARS-CoV-2 IgY against the RBD. (F) Neutralization of pseudoviruses listed in (D) by human serum
of immunized individuals. (G) Neutralization of live D614G vs. Delta variants by human serum of immunized individual or by anti-SARS CoV-2 IgY. Microscopic
evaluation of monolayers of Vero E6 cells after 96 hours infection with the indicated authentic (live) SARS-CoV-2 variant. Images from infected cells are shown after 4
days of infection with SARS-CoV-2 variants in the absence or presence of test items. Top three panels: Infection in the presence of MEX-BC2/2020 and bottom
three panels: infection with the Delta variant each in the presence of vehicle alone, serum of a person immunized twice with the Moderna (mRNA-1273) vaccine or
anti-SARS CoV-2 RBD IgY, as indicated, all at the indicated concentration (neutralization experiments in panels D-H & I were conducted by RetroVirox using
pseudovirus or live virus, as indicated). (H) Binding of anti-SARS-CoV-2 RBD IgY to the index virus and Omicron variant (B.1.1.529) RBD domain using ELISA.
(I) Neutralization of live index or Omicron variant of SARS-CoV-2 by anti-SARS-CoV-2 RBD IgY. Except when indicated, the studies were done over several months;
therefore, the absolute titers in the ELISA and neutralization studies were not identical. However, each experiment included the same positive control; index RBD for
ELISA and index virus for neutralization assays.

Theta, Iota, and Mu variants and 1 of the 2 substitutions in the
Kappa variant (Figure 4A). The IC50 of the VSV-S pseudovirions
for the index strain and Beta variant were virtually identical: 668
mg/mL for the index strain, 568 mg/mL for Beta (Figure 4D), and
2-fold lower for Alpha (IC50 = 302 mg/mL; Figure 4D).
RetroVirox also provided data using plasma from a single
Moderna-vaccinated individual for a titer comparison of
neutralization with anti-SARS-CoV-2 RBD IgY, tested with 3
of the variants. In a side-by-side study, the IC50 generated with
the human plasma from a recipient of the mRNA Moderna
vaccine (2 doses; index SARS-CoV-2) showed the highest titer
against the index virus, followed by a 2.8-fold drop in titer
towards Alpha and a 6.7-fold lower titer for Beta (Figure 4F).
The anti-SARS-CoV-2 IgY preparation was similarly effective
against the Delta variant compared with the index strain
(Figure 4E). The assays show that Y0180 displays similar

First, IgY antibody ELISA titer against Beta RBD was
compared with the RBD of the index SARS-CoV-2 virus as
well as the most common Alpha variant. ELISA with
recombinant full-length S protein or the RBD of the 3 mutants
as well as the immunizing RBD fragment of the index virus
yielded a virtually identical titer (Figure 4C). Although the
Omicron variant still uses the hACE2 receptor to infect human
cells (11, 36), the RBD contains a total of 15 mutations compared
to the index virus, 11 of which were not found in the previous
variants (Figures 4A, B). Yet, the ELISA titer of IgY against the
Omicron RBD was also equivalent or slightly better than that
towards the RBD of the index virus (Figure 4H).
Next, we tested the neutralization titer of anti-SARS-CoV-2
RBD IgY (lot Y0180) against the RBD of the index, Alpha, and
Beta variants, thus including all the amino acid substitutions
within the RBD also found in the RBD of Gamma, Zeta, Eta,
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cytokines (22 of the 27 tested) in both placebo- and IgY-treated
groups at any time. Compared with D1 H0, we detected a
transient, slight increase in interleukin-1 (IL-1) beta and
monocyte chemoattractant protein-1 (MCP1) on Day 1, 4
hours after anti-SARS-CoV-2 RBD IgY administration. A
similar trend that did not reach signiﬁcance was also observed
in the placebo group at the same time; increases in IL-1 beta and
MCP1 were not seen at any other time. There was a signiﬁcant
increase in interferon-inducible protein 10 (IP10) on Day 1, 4
hours after the ﬁrst treatment compared to D1 H0, observed in
both treatment and placebo group. A signiﬁcant decrease in D1
H24 in the placebo arm was observed only for RANTES.
Nonetheless, none of these changes in cytokines were observed
in the rats at other time points. Together, our data show that
long-term twice-daily administration of 4 mg/mL IgY (or 16 mg/
kg) up to 28 days in rats has excellent safety and tolerability with
no evidence of systemic immune activation.

neutralizing activity against both isolates, with slightly reduced
neutralizing activity against Omicron (Figures 4E, I); IC50 values
generated were 635 mg/mL (Delta) and 739 mg/mL (index virus).
The neutralization assay against Omicron generated IC50 values
of 143 mg/mL (index) and 785 mg/mL (Omicron) (Figure 4I).
Plasma from one Moderna-vaccinated individual was also tested
in parallel with both isolates. NT50 values generated with this
plasma against the variants were 1:1274 (Delta pseudovirus) and
1:1091 (index pseudovirus). The neutralization activities of the
antibody and control plasma against both variants were also
conﬁrmed by microscopy evaluating the virus-induced
cytopathic effect in infected cell monolayers Figure 4G). The
human serum had a similar degree of neutralization against the
index pseudovirus and Delta (Figure 4G) when tested at a dose
that is three times higher than that required for 50%
neutralization (1:640 in Figure 4G, middle panels, vs. 1:2,000
in Figure 4F). In contrast, anti-SARS-CoV-2 IgY tested at 400
µg/mL (Figure 4G, right panels), a dose below that required for
50% neutralization (~650 µg/mL; Figure 4E), was equally
effective against both variants. Limited information can be
drawn based on a single Moderna vaccinated individual, but
other data about the reduced titer of humans immunized with
this vaccine towards various variants conﬁrm our ﬁndings (37).
Together these data indicate that the spectrum of the polyclonal
anti-SARS-CoV-2 RBD IgY displays sufﬁcient diversity so that
none of the common point mutations in the RBD associated with
a greater transmission rate of the virus affected the neutralization
efﬁcacy of these most common SARS-CoV-2 variants of concern.

3.6 Human Tissue Cross-Reactivity Study
We determined potential cross-reactivity of the anti-SARS-CoV2 RBD IgY protein to a full panel of human tissues (at least 3
donors per tissue; see Supplementary Table S4 for a list of
human tissues tested for reactivity). Anti-SARS-CoV-2 RBD IgY
reactivity at two concentrations (20 and 10 µg/mL) was
compared with control polyclonal chicken IgY antibodies
(negative control), and with anti-human macroglobulin
(positive control for staining). No speciﬁc binding was
observed with the anti-SARS-CoV-2 RBD IgY to any of the
human tissue panels examined, including human nasal cavity
and lung (see Figure 6).

3.4 Efﬁcacy Study in a Hamster Model
of COVID-19
We did not ﬁnd in vivo efﬁcacy of anti-SARS-CoV-2 RBD IgY in the
Syrian golden hamster COVID-19 model against a challenge with a
titer of 0.8 or 4 x 106 of SARS-CoV-2 virus, likely because the
amount of virus we employed was too high. Lung viral load after 3
days was comparable between the control treatment group and the
anti-SARS-CoV-2 RBD IgY treatment group. (Supplementary
Figure S2). By Day 3, all hamsters lost between 5 and 10% of
their weight, without a signiﬁcant difference between the groups

3.7 Phase 1 Clinical Trial Results

3.5 Rat Toxicity and Safety Study

3.7.1 Baseline Demographics

All 8-week-old Sprague Dawley rats (10 males and 10 females) in
the 28-day GLP safety study survived to scheduled euthanasia
with no mortality, test article-related organ weight changes, or
gross or microscopic ﬁndings (see Figures 5A, B). There were
also no differences between female and male groups in each
treatment arm. The GLP-qualiﬁed assay detected no anti-SARSCoV-2 RBD IgY in the sera of animals after 28 days of daily
treatment with 4 mg anti-SARS-CoV-2 RBD IgY (lower limit of
detection of 30 ng/mL).
There was no evidence of signiﬁcant systemic immune
activation in the rats (20/group) treated as above by measuring
changes in levels of 27 proinﬂammatory serum cytokines after
anti-SARS-CoV-2 RBD IgY administration (Figure 5C). When
comparing posttreatment (Day 1 at 4 hours and Day 28 at 24
hours after twice-daily treatments) to pretreatment serum levels
(Day 1, time 0; D1 H0), there were no changes for most of the

Study participants ranged in age from 20 to 43 years (median,
25.5) in the single-dose part of the study and 18 to 40 years
(median, 23.0) in the multiple-dose part (Tables 1, 2). Female
participants comprised 75% of the population in the single-dose
study segment and 46% in the multiple-dose study segment.
Demographics are summarized in Tables 1, 2.
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Forty-seven of 48 enrolled participants completed the study drug
treatment period and planned study visits (Supplementary
Figure S1, CONSORT ﬂow diagram). One participant in the
multiple-dose part was withdrawn from the study after receiving
3 doses (Day 1) of placebo due to a concurrent upper respiratory
tract infection, judged to be unrelated to study drug by
the investigator.

3.7.2 Safety and Tolerability
The overall incidence of treatment-emergent adverse events was
29% (7 of 24 participants; Table 3) in the single-dose part of the
study and 58% (14 of 24 participants; Table 4) in the multipledose part of the study, with similar incidence rates between antiSARS-CoV-2 RBD IgY (42%) and placebo (50%) groups. The
most frequent treatment-emergent adverse event was headache,
with similar rates between placebo (17%) and anti-SARS-CoV-2
RBD IgY (14%) (Tables 3, 4).
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A
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C

FIGURE 5 | Preclinical toxicity of 28-day treatment with anti-SARS-CoV-2 RBD IgY in rats. (A) Study design. (B) Summary of ﬁndings. (C) Serum levels of 27
cytokines over time in rats treated with IgY (Tx) or vehicle/placebo (PL). Data are provided for Day 1 before treatment (D1H0); Day 1, 4 hours after the treatment
(D1H4); 24 hours after the two treatments, 6 hours apart, at 24 hours after the ﬁrst treatment (D1H24); 28 days of twice-daily treatments and 4 hours of the
treatment of that day (D28H4); and 28 days of twice-daily treatments and 24 hours of the treatment of that day (D28H24). Red indicates a statistical difference with a
false discovery rate (FDR) signiﬁcant p-value (p < 0.05).

treatment (D2 pre-dose), and 2 hours after the ﬁrst dosing on day
2 (D2 H2; Supplementary Figure S3). There were slight but
statistically signiﬁcant decreases (red histograms) in 10 of the 80
cytokines (Supplementary Figure S3). These slight declines in
CCL27, CXCL9, IL23, IL27, LIF, MIP5, RESISTIN, TNFa,
TNFa, and TNFRSF6 were noted only in the 12 mg/day group
compared to the pretreatment levels. These declines also
occurred only 2 hours after the ﬁrst dose (D1 H2) and were
not sustained, except for MIP5. There was also a small decrease
in IL3, 2 hours after the ﬁrst dose of 6 mg/day group anti-SARSCoV-2 RBD IgY, but there were no changes in this cytokine at
any other times or doses. These slight changes, which were also
not sustained or dose dependent, were judged to be artifactual.
Overall, there were no clinically relevant increases in serum
cytokines at any time for any of the treatment groups (6, 12, or 24
mg total daily dose of anti-SARS CoV-2 RBD IgY for 14 days).

All adverse events were mild (grade 1) in severity. No serious
adverse event or lab-related adverse event was reported, and
there was no dose dependency of adverse events observed.
Furthermore, no participant receiving anti-SARS-CoV-2 RBD
IgY had an adverse event of nasal irritation or nasal congestion.
There were no clinically signiﬁcant observations or trends noted
in laboratory assessments, vital signs, physical exam ﬁndings, or
electrocardiograms during the study.

3.7.3 Pharmacokinetics
PK analyses indicated no evidence of serum anti-SARS-CoV-2
RBD IgY above the lowest detection levels of 30 ng/mL (using a
GLP study at Charles River Laboratories) before and after 14
days of treatment in the 18 participants who received anti-SARSCoV-2 RBD IgY in the multiple-dose part of the study.

3.7.4 Serum Cytokines
Levels of 80 different cytokines in the sera of 19 participants of
the multiple-dose part were tested before treatment (D1 predose), 2 hours after dosing on Day 1 (D1 H2); Day 2, before
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3.7.5 IgE and Anti-IgE
The anti-SARS-CoV-2 IgY preparation contains ovalbumin.
Although participants with egg allergies were excluded from

11

June 2022 | Volume 13 | Article 899617

Frumkin et al.

Anti-SARS-CoV-2 IgY Intranasal Prophylaxis

FIGURE 6 | Lack of cross-reactivity of anti-SARS-CoV-2 RBD IgY with human tissues. Immunohistochemical testing of anti-SARS-CoV-2 RBD IgY (top row), control
IgY (middle row; negative control), and anti-human macroglobulin antibodies (bottom row; positive control) with human nasal mucosa (left two panels) and human
lungs (right two panels). Bars provide a magniﬁcation scale.

TABLE 1 | Demographics of participants in single-ascending dose group (Part 1).
Anti-SARS-CoV-2 IgY

Age, years
Mean (SD)
Median (range)
Gender, n (%)
Female
Male
Ethnicity, n (%)
Hispanic or Latino
Not Hispanic or Latino
Race, n (%)
Asian
Native Hawaiian or OtherPaciﬁc Islander
White

2 mgN=6

4 mgN=6

8 mgN=6

Placebo N=6

All Participants N=24

28.8 (7.99)
26.5 (20-43)

27.3 (4.76)
28.0 (21-33)

27.7 (5.65)
27.5 (20-37)

22.7 (2.34)
22.0 (20-27)

26.6 (5.72)
25.5 (20-43)

4 (66.7)
2 (33.3)

4 (66.7)
2 (33.3)

4 (66.7)
2 (33.3)

6 (100)
0

18 (75.0)
6 (25.0)

1 (16.7)
5 (83.3)

0
6 (100)

0
6 (100)

0
6 (100)

1 (4.2)
23 (95.8)

2 (33.3)
0
4 (66.7)

1 (16.7)
0
5 (83.3)

0
0
6 (100)

0
1 (16.7%)
5 (83.3)

3 (12.5)
1 (4.2%)
20 (83.3)

the trial, an exploratory analysis was conducted of the
pretreatment serum total IgE and anti-IgE antibody (mainly
anti-ovalbumin) levels in the 24 participants in the multiple-dose
part of the trial. No participant had detectable serum egg-white
speciﬁc IgE antibodies (all <0.35 kU/L).

worldwide. Limitations to current vaccines include global
vaccine availability and affordability, vaccine hesitancy, and
rapidly emerging highly infective viral strains that escape
vaccine-induced immunity. This has been particularly apparent
following the emergence of Delta and Omicron. The latter variant
was ﬁrst detected in specimens collected on November 8, 2021
(38). Within a few weeks, the variant became the dominant SARSCoV-2 variant in the United States (39) and is now the most
common strain globally (14). Both convalescent sera from early
strain-infected patients and fully vaccinated individuals exhibited
a low neutralization capacity against Omicron (11–13); a
reduction of 30 to 40-fold in neutralization titers was reported.

4 DISCUSSION
Despite recent successes in generating highly effective COVID-19
vaccines, there is an ongoing need for widely available and safe
antiviral strategies that reduce infection and transmission
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TABLE 2 | Demographics of participants in the multiple-dose group (Part 2).
Anti-SARS-CoV-2 IgY

Age, years
Mean (SD)
Median (range)
Gender, n (%)
Female
Male
Ethnicity, n (%)
Hispanic or Latino
Not Hispanic or Latino
Race, n (%)
Asian
Black or African American
White

2 mg TID N=6

4 mg TID N=6)

8 mg TID N=6

Placebo TID N=6

All Participants N=24

26.0 (8.37)
23.0 (18-40)

21.8 (2.14)
22.0 (19-25)

27.5 (6.92)
25.0 (21-37)

25.3 (6.41)
25.0 (18-36)

25.2 (6.33)
23.0 (18-40)

1 (16.7)
5 (83.3)

4 (66.7)
2 (33.3)

2 (33.3)
4 (66.7)

4 (66.7)
2 (33.3)

11 (45.8)
13 (54.2)

0
6 (100)

0
6 (100)

1 (16.7)
5 (83.3)

1 (16.7)
5 (83.3)

2 (8.3)
22 (91.7)

1 (16.7)
0
5 (83.3)

2 (33.3)
0
4 (66.7)

2 (33.3)
0
4 (66.7)

2 (33.3)
1 (16.7)
3 (50.0)

7 (29.2)
1 (4.2)
16 (66.7)

tid, 3-times daily.

TABLE 3 | Adverse events by preferred term- single ascending-dose study (Part 1).
Anti-SARS-CoV-2 IgY

Participants with ≥1 TEAE
MedDRA Preferred Term
Fatigue
Erythema
Headache
Sneezing
Tension headache
Thermal burn

2 mg
(N=6)
n (%) E

4 mg
(N=6)
n (%) E

8 mg
(N=6)
n (%) E

Placebo
(N=6)
n (%) E

All Participants
(N=24)
n (%) E

1 (16.7%) 1

2 (33.3%) 2

2 (33.3%) 2

2 (33.3%) 2

7 (29.2%) 7

0
0
0
0
1 (16.7%) 1
0

0
0
1 (16.7%) 1
1 (16.7%) 1
0
0

1 (16.7%) 1
1 (16.7%) 1
0
0
0
0

1 (16.7%) 1
0
0
0
0
1 (16.7%) 1

2 (8.3%)
1 (4.2%)
1 (4.2%)
1 (4.2%)
1 (4.2%)
1 (4.2%)

2
1
1
1
1
1

E, number of events; n, number of participants; TEAE, treatment-emergent adverse event.

TABLE 4 | Adverse events by preferred term- multiple-dose study (Part 2).
Anti-SARS-CoV-2 IgY

Participants with ≥1 TEAE
MedDRA Preferred Term
Headache
Upper respiratory tract infection
Contusion
Dental discomfort
Dizziness
Ear pain
Epistaxis
Eyelid irritation
Injection site hematoma
Nasal congestion
Parosmia
Presyncope
Rhinorrhea
Skin abrasion
Tenderness

2 mg TID
(N=6)
n (%) E

4 mg TID
(N=6)
n (%) E

8 mg TID
(N=6)
n (%) E

Placebo TID
(N=6)
n (%) E

All Participants
(N=24)
n (%) E

4 (66.7%) 7

2 (33.3%) 3

4 (66.7%) 5

4 (66.7%) 5

14 (58.3%) 20

0
0
0
1 (16.7%)
1 (16.7%)
1 (16.7%)
1 (16.7%)
0
1 (16.7%)
0
0
1 (16.7%)
0
0
1 (16.7%)

0
0
0
0
0
0
0
0
0
0
1 (16.7%) 1
0
1 (16.7%) 1
1 (16.7%) 1
0

3 (50.0%) 3
1 (16.7%) 1
0
0
0
0
0
1 (16.7%) 1
0
0
0
0
0
0
0

2 (33.3%) 2
1 (16.7%) 1
1 (16.7%) 1
0
0
0
0
0
0
1 (16.7%) 1
0
0
0
0
0

5 (20.8%) 5
2 (8.3%) 2
1 (4.2%) 1
1 (4.2%) 1
1 (4.2%) 1
1 (4.2%) 1
1 (4.2%) 1
1 (4.2%) 1
1 (4.2%) 1
1 (4.2%) 1
1 (4.2%) 1
1 (4.2%) 1
1 (4.2%) 1
1 (4.2%) 1
1 (4.2%) 1

1
1
1
1
1

1

1

E, number of events; n, number of participants; TEAE, treatment-emergent adverse event.
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has been extensively evaluated in humans (49–54). Human
immunoglobulins G (IgG) and A given intranasally are well
tolerated (49–54), including in pediatric populations. Our
decision to protect from viral entry at the nasal mucosa stems
from the observation that levels of lung hACE2 are much lower
than in the nose; infection of lung tissue is >5 orders of
magnitude lower compared with nasal mucosa (55, 56).
Therefore, inhibition of viral entry at the nose is likely the
correct target site for optimal efﬁcacy.
Our product is egg-derived immunoglobulins, which could
contain potentially antigenic residual chicken proteins. However,
it is not indicated for those who are allergic to egg yolks. Note
also that most humans are exposed to egg-derived antigens
through their diet and are not allergic. Furthermore,
anaphylaxis for those who consume eggs regularly is rare.
However, the safety and tolerability of hen-derived IgY as an
intranasal treatment in humans have not been described despite
their extensive use in a variety of routes in animals and
aquaculture (41, 57).
Several other studies have examined anti-COVID-19
intranasal prophylaxis, mostly in animal models (58–65).
These prophylaxes include polymer barriers, active vaccines,
existing antiviral drugs, inhibitors of protease-induced
activation of the virus, antiseptics, antimicrobial agents, and
antibodies. Most relevant for comparison with our study is the
use of neutralizing antibodies. In one study, intranasal treatment
with a monoclonal human antibody (500 mg in 100 mL/nare) 12
hours after infection in hamsters inoculated with 5 x 104 median
tissue culture infective dose (TCID50) of SARS-CoV-2 decreased
clinical disease signs and improved recovery during the 9 days of
infection compared with control antibody-treated hamsters (65).
However, in contrast to our study, there was a substantial
systemic exposure to the human antibody 24 hours after a
single intranasal treatment with 2.5 mg; serum levels of the
treated antibodies in that study were 210 ng/mL vs. below
detection levels (30 ng/mL) in our study following
administration of 4 mg IgY antibodies intranasally daily for up
to 28 days. Therefore, the beneﬁt of the treatment in their study
(65) could have been due to neutralization of the virus that had
entered the body rather than blocking entry of the virus at the
nasal mucosa. Similarly, a single intranasal monoclonal
immunoglobin M (IgM) antibody administration in a mouse
model of COVID-19 was highly efﬁcacious when mice were
infected with 104 PFU (62). Human IgM systemic exposure was
also noted in mice treated with human IgM monoclonal
antibody anti-SARS-CoV-2, although the study attributed the
protection to the persistent presence of the antibody at the nasal
cavity for over 48 hours based on ﬂuorescent tag measurement
(60). Such long persistence of levels of IgM in the nasal cavity is
at odds with other studies, including when using 99mTc-labeled
albumin particles or ﬂuorescently labeled IgY antibodies that
showed a residence time of 2-4 hours (42). If the long persistence
is not an artifact of the method, it may suggest a unique beneﬁt of
IgM treatment as COVID-19 prophylaxis. Note, however, that
with one exception (62), none of these studies assessed the crossreactivity of antibodies against the variants.

Furthermore, of the eight currently authorized or approved
monoclonal antibodies, seven did not neutralize the Omicron
variant and one had a 3-fold reduction in neutralization titer (12).
These data highlight the need for alternative and complementary
approaches to curb COVID-19.
Here, we describe the production of the ﬁrst chicken egg yolkderived anti-index SARS-CoV-2 RBD IgY polyclonal antibodies
as an intranasal drop product for humans with equal in vitro
activity against all variants of concern. These IgY were raised in
SPF hens and showed an excellent safety proﬁle when given
intranasally by drops to rats for 28 days (4 mg/day). No toxicity,
innate inﬂammatory response, or systemic exposure to IgY were
noted in this GLP study. In 48 healthy adult participants, antiSARS-CoV-2 RBD IgY given intranasally at single-ascending
doses of 2, 4, and 8 mg and as total daily doses of 6, 12, and 24 mg
for 14 days also had a highly favorable safety and tolerability
proﬁle. Importantly, no participant receiving intranasal antiSARS-CoV-2 IgY in the multiple-dose phase had measurable
levels of anti-SARS-CoV-2 RBD IgY in their sera, reﬂecting the
absence of systemic absorption of topically administered IgY
following intranasal application. We also found no evidence of a
systemic inﬂammatory immune response triggered by the topical
treatment with anti-SARS-CoV-2 RBD IgY in humans, and no
detectable increase in 80 sera cytokines.
Hen-derived IgY antibodies have several advantages for topical
use in humans; these antibodies do not bind the Fc receptor or
rheumatoid factor or activate the human complement cascade
(40), thus greatly reducing the risk of severe immune responses.
These features support the clinical applications of IgY for nasal
treatment in a wide range of persons, including the elderly,
immunocompromised, and children. IgY antibodies have been
beneﬁcial with favorable safety and tolerability when given
prophylactically in both animal models and clinical settings of
viral diseases, including respiratory infections [reviewed in (41)].
Overall, available data to date suggest that IgY preparations given
by nonparenteral administration do not have unwanted off-target
proinﬂammatory effects and are nontoxic to humans, thus
permitting potential clinical applications in diverse populations
and diseases.
The potential use of IgY from hens immunized with
inactivated virus (42), recombinant S protein (43–46), or N
protein (47) has been explored with studies evaluating
neutralization of the virus in cells, with effective inhibition
values, 1 mg/mL (43), 16.8 mg/mL (46), and 0.27 mg/mL (44).
However, the ability of these egg-derived antibodies to neutralize
other common SARS-CoV-2 variants has not been evaluated and
their safety proﬁle in animals or humans has not been assessed.
Intranasally administered proteins are removed from the
mucosal surface through ciliary movement (42, 48), which was
the basis for using a 3-times daily (every 4 hours) regimen in
our phase 1 study. The anti-SARS-CoV-2 RBD IgY was
designed to capture and immobilize SARS-CoV-2 on the
nasal mucosa, preventing the virus from binding to and
spreading across the nasal mucosa, and also preventing the
transmission of the virus to other individuals. Intranasal
delivery of mammalian immunoglobulins as antiviral agents
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of intranasal anti-SARS-CoV-2 IgY for 14 days had an excellent
safety proﬁle in humans; this daily dose represents ~1/20 of one
egg of immunized SPF hen and ~1/5 of an egg of commercial
hen, underscoring that such an IgY dose is feasible for both
production cost and effort.
There are some limitations to our studies. Our phase 1 clinical
trial in healthy volunteers was to assess initial safety, tolerability,
and PK of anti-SARS-CoV-2 IgY and was not designed to
evaluate efﬁcacy. In addition, we were unable to obtain in vivo
data showing viral neutralization (Supplementary Figure S2).
This may reﬂect using too much virus in this animal model of
COVID-19; our study used 8 x 105 or 4 x 106, vs. 1 or 5 x 104
TCID50 (63, 65). In addition, our intranasal formulated IgY
preparation was viscous to obtain better delivery in humans. As
hamsters are obligatory nose-breathers, they may have blown out
the formulated IgY. Finally, the virus that was delivered in 50 mL
of liquid directly into each nare may have washed out some
antibodies. However, a recent study demonstrated a protective
effect of intranasal administration of anti-RBD IgY in hamsters
challenged with SARS-CoV-2 (64), which suggests that our
prophylactic will also be protective. Another limitation in our
study is that the neutralization studies comparing the hen IgY vs.
human sera were not comprehensive and included only 1 or 2
human samples. Nevertheless, our study is the ﬁrst to
demonstrate that anti-SARS-CoV-2 IgY against all the current
variants of concern had a favorable safety proﬁle when used
chronically as intranasal drops in rats and humans.
There are also several advantages for the use of IgY as
prophylaxis against other pathogens besides SARS-CoV-2 that
cause disease in humans. As we noted above, IgY generation is
inexpensive and fast; one egg of an SPF hen produces 20-80 daily
doses (at 6 mg/dose) within 3 weeks from the ﬁrst injection (1
week after the ﬁrst boost). We found a limited variability between
individual immunized hens as determined by ELISA and
Western blot analyses and a batch-to-batch consistency
(Figures 3A-F). IgY is also easy to distribute; besides the
known long-term stability of puriﬁed IgY (68), we also found
excellent stability of the formulated material at 2-8°C for at least
6 months (maximum time point measured so far) and greater
than 2 weeks when stored at room temperature. This is in
contrast to vaccines, some of which require cold-chain storage
at -80°C that complicates the coordination of global distribution
and to resource-poor regions, in particular.
Another important advantage of IgY-based prophylaxis is the
ease of local production, including in low- and middle-income
countries. As hen immunization is a standard procedure around
the world, IgY puriﬁcation and formulation do not require
expensive equipment and are simple to conduct. In a separate
study, we developed a step-by-step protocol for IgY puriﬁcation
in low- and middle-income countries using inexpensive, readily
available materials in place of costly specialized laboratory
equipment and chemicals (69). Therefore, anti-SARS-CoV-2
IgY can be readily made available worldwide as an additional
means of reducing SARS-CoV-2 infection. Each day, one
immunized hen can produce the daily dose required for
prophylaxis of a family. In addition, by reducing viral mobility

Our work shows that, although the IgY was raised against the
ancestral (index) strain RBD, the repertoire of the antibodies
raised in hens was diverse and polyclonal so that binding
afﬁnities measured by ELISA for the single (Alpha), double
(Delta), and triple amino acid (Beta) substitutions, or the
Omicron variant with 15 amino acid substitutions in the RBD
were similar to the afﬁnity for the index RBD or full-length S
protein (Figures 4C, H). We then conﬁrmed that there was no
difference between Alpha, Beta, and Delta variants, and the index
strain in a neutralization assay in culture using a VSV-S
pseudovirus or live virus (Figures 4D, E, I), whereas a reduced
neutralization activity of human serum was observed in side-byside experiments (Figures 4F, G). The viral neutralization
studies reported here were conducted by a commercial
provider (RetroVirox) and by an established laboratory at the
USAMRIID, both comparing the results with either convalescent
sera or an immunized human, for relative titer evaluation.
The culture neutralization titer of anti-SARS-CoV-2 RBD IgY
is lower than the human anti-SARS-CoV-2 sera (e.g.,
Figuress 4F vs. 4D). However, this may reﬂect the need for
protease-induced RBD exposure in the full-length S protein for
binding by IgY, which might not occur effectively in the culture
model. A comparison of titer values between our product and
sera from an immunized person can also be calculated based on
values of IgG levels in human sera (~15 mg/mL); a titer of 1:2,000
(Figure 4F; dashed line) is equivalent to ~7 ug/mL or 100-fold
higher IgG titer than our IgY (Figure 4D; ~600 ug/mL).
However, as the dose of the IgY anti-SARS-CoV-2 preparation
in humans is planned to be 4 mg/dose, more important is the
equal potency of the IgY towards the various variants when used
even at ~1/10 of the intended IgY dose (Figures 4E, I).
Another potentially important difference between our
ﬁndings and the previously published study is the antigen used
to raise the antibodies. When expressed in mammalian cells, the
full-length S1 protein has at least 22 glycosylation sites per S
monomer (66). As glycosylated amino acids are more
immunogenic, the afﬁnity of the human antisera may reﬂect
binding to the glycosylated determinants of the protein.
However, as glycosylation sites in the S1 protein are heavily
mutated and new sites may be formed in many of the variants
(34), immune reactivity that is biased towards glycosylated sites
may lead to loss of activity as the virus mutates. This will not
occur when the non-glycosylated RBD is used as the
immunogen, as we have done in our study using cell-free
expressed RBD (22, 23). Supporting the negative impact of
glycosylated antigen, increased immunogenicity of protein
antigens after removal of glycosylation sites has been
previously shown for hepatitis C virus envelope antigen-based
vaccines (67). Furthermore, the apparent higher titer in the
neutralization assay may be biased if the tested virus has the
same glycosylation sites as that used as an immunogen in
vaccinated individuals; many studies use the original viral
isolates rather than the common current variants.
An important feature of our product is the ease of developing
prophylaxis that can be quickly and inexpensively produced. We
found that 24 mg total daily dose (divided into three equal doses)
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Clinical Practice, and all applicable federal, state, and local laws,
rules, and regulations. The patients/participants provided their
written informed consent to participate in this study. The animal
study was reviewed and approved by Charles River Laboratories
Institutional Animal Care and Use Committee before conduct.
The hamster efﬁcacy study was conducted following the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health and
the protocol was approved by the Institutional Animal Care and
Use Committee at the Washington University School of
Medicine (assurance number A3381–01). Stanford Institutional
Animal Care and Use Committee did not initially review the
animal studies because they were not conducted at Stanford but
were retroactively approved.

and anchoring the virus to the nasal mucus, transmission of the
virus from infected to healthy individuals may be reduced.

5 CONCLUSION
The current COVID-19 pandemic illustrates the need for
prophylactics that can be produced rapidly at low cost, are
technically accessible anywhere in the world, and complement
traditional vaccine development. The safety and beneﬁt of IgY
and the ease to produce it at low cost are well described for
animal farms. In contrast, the clinical adaptation of IgY for
human use has been slow, likely hampered by a lack of economic
beneﬁt that has hindered commercial development by industry.
For that reason, we undertook the effort of establishing the ability
of anti-SARS-CoV-2 IgY to neutralize variants of concern and
the initial safety of the IgY preparation using industry GLP and
GMP standards. We suggest that until vaccination that is highly
effective against prevalent variants becomes available worldwide
or community immunity is achieved, intranasal delivery of antiSARS-CoV-2 IgY may provide passive immunization, including
for use as an add-on to personal protective equipment and other
preventive measures for the general population. This IgY may
also provide short-term protection in addition to vaccines in less
well-ventilated environments, such as trains, airplanes, and
lecture halls. We also suggest that this approach has the
potential to provide a means to curb new threats of epidemics
by airborne infectious agents; by providing the relevant
immunogen for hen immunization at the geographical site
where the threat was detected, an effective passive immunity
can be initiated locally to stop the spread of the airborne
infectious agent before it becomes an epidemic. We hope that
this study will trigger further work to evaluate the safety and
efﬁcacy of anti-SARS-CoV-2 IgY in those at risk of SARS-CoV2 infection.
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